VRDN Q2 2023 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72,000-71.9% YoY

Gross Profit

$72,000100.0% margin

Operating Income

-$59M-82326.4% margin

Net Income

-$55M-76476.4% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

-26.5%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$46M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$351M

Total Liabilities

$36M

Stockholders' Equity

$316M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72,000	$256,000	-71.9%
Gross Profit	$72,000	-$21M	+100.3%
Operating Income	-$59M	-$30M	-100.5%
Net Income	-$55M	-$29M	-86.7%

Revenue Segments

Collaboration Revenue

$100,000100%